Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q3 2023 · 10-Q
Revenue—
Net Income-$1.92M-$1.92MN/M vs Q3 2022 EPS Diluted-$4.90-$4.90N/M vs Q3 2022 Operating Income-$2,080,890N/M Operating Cash Flowderived-$2,555,223N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end